Opthea Limited,a clinical-stage biopharmaceutical Company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), announced executive leadership changes in Finance and Commercial as well as senior hires for Biometrics, Clinical Operations and Market Access.
“Opthea is at a key inflection point with the sozinibercept Phase 3 topline data readouts for COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025,” said Frederic Guerard, PharmD, Chief Executive Officer of Opthea. “We made several senior hires and executive changes to further deepen our team’s expertise in retina, expand our clinical capabilities, while advancing Opthea’s commercial readiness.”
“On behalf of the Board of Directors and the entire Opthea team, I would like to thank Judy Robertson, Peter Lang and Bruno Gagnon for their leadership and significant contributions in Opthea’s journey from a development-stage biopharmaceutical Company to a commercial-ready organization,” continued Dr. Guerard. “We wish them continued success in their professional and personal lives.”
Daniel Geffken, Co-Founder and Managing Director, Danforth Advisors, will assume the role of Chief Financial Officer on an ad interim basis reporting to Frederic Guerard, PharmD, Chief Executive Officer, Opthea, effective September 9, 2024.
Mike Campbell has been appointed Chief Commercial Officer, reporting to Frederic Guerard, PharmD, Chief Executive Officer, Opthea.
Dayong Li, PhD, has been appointed Senior Vice President, Biometrics, reporting to Julie Clark, MD, Senior Vice President, Clinical Development. Jen Watts has been appointed Vice President Global Clinical Operations.Anthony Bonifazio has been appointed Vice President, Market Access.
Comments powered by CComment